Merck Animal Health Expands Vaccine Portfolio And Manufacturing Capabilities With Its Acquisition Of Prondil S.A.

Share

Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced it has acquired Prondil S.A., a privately-held company specializing in development and manufacturing of animal health vaccines for livestock. Specific terms of the agreement were not disclosed.

Prondil, located in Montevideo, Uruguay, is an internationally-recognized supplier of quality antigens and vaccines for veterinary use. The company’s wide range of products are sold in over 20 countries.

“At Merck Animal Health we continue to execute upon our strategy to expand our vaccine leadership and add more breadth to our portfolio,” said Rick DeLuca, President, Merck Animal Health. “This acquisition of Prondil provides expertise and biologics manufacturing capacity as well as a complementary portfolio of specialized livestock vaccines.”

Vaccines play an important role in protecting animal and public health. Timely and effective vaccination reduces the incidence and severity of disease, enabling efficient production of food animals.


Facebooktwitterlinkedinmail

Leave a Reply